New Molecular Test Available to Diagnose Trichomonas vaginalis in Asymptomatic and Symptomatic Females

- BD ProbeTec ™ Trichomonas vaginalis Qx Assay Launches on the BD Viper™ System in Europe

BALTIMORE, Oct. 18, 2012 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today the European launch of the BD ProbeTec™ Trichomonas vaginalis Qx Amplified DNA Assay for the direct qualitative detection of T. vaginalis DNA in female urine specimens to aid in the diagnosis of trichomoniasis on the BD Viper™ System. This assay has been CE-marked to the In Vitro Diagnostic Directive (98/79/EC).

Trichomoniasis is the most common curable sexually transmitted infection (STI). Worldwide, more than 180 million cases are estimated to occur annually.  Genital inflammation caused by trichomoniasis can increase a woman's susceptibility to HIV infection. In HIV-infected women, trichomoniasis may increase the likelihood of HIV transmission to sex partners.  Furthermore, trichomoniasis is often asymptomatic. For these reasons, experts recommend screening for T. vaginalis in women considered to be at high risk for infection (i.e., women who have new or multiple partners, have a history of STIs, exchange sex for payment, or use injection drugs).  

"The global prevalence of trichomoniasis is on the rise and there are more asymptomatic cases than previously thought," said Chris Demiris, Worldwide Group Marketing Manager, BD Diagnostics - Women's Health and Cancer.  "The availability of an automated platform is especially important as clinical and public health communities embrace the need for a test that provides timely and accurate diagnosis of trichomoniasis when screening high-risk populations."

The BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay is designed for use with the BD Viper System. Automated DNA extraction and simultaneous amplification and detection maximize laboratory efficiency and quality of results. Compared to wet mount microscopy and culture, the BD ProbeTec Trichomonas vaginalis Qx assay reduces human intervention and associated variables and improves speed to results. The BD Viper System allows laboratories to test other samples for chlamydia, gonorrhea and herpes on the same automated platform. 

For more information on the BD ProbeTec Trichomonas vaginalis Qx Amplified DNA Assay, please visit http://www.bd.com/ds/productCenter/MD-Viper.asp.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:
Jamie Yacco
Public Relations
+1-201-847-4796
Jamie_Yacco@bd.com